Blue Jet Healthcare Limited Just Missed Earnings - But Analysts Have Updated Their Models

The annual results for Blue Jet Healthcare Limited (NSE:BLUEJET) were released last week, making it a good time to revisit its performance. Revenues of ₹7.4b were in line with forecasts, although statutory earnings per share (EPS) came in below expectations at ₹9.44, missing estimates by 5.7%. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

View our latest analysis for Blue Jet Healthcare

Taking into account the latest results, the consensus forecast from Blue Jet Healthcare's three analysts is for revenues of ₹10.0b in 2025. This reflects a huge 35% improvement in revenue compared to the last 12 months. Per-share earnings are expected to surge 39% to ₹13.15. Before this earnings report, the analysts had been forecasting revenues of ₹10.4b and earnings per share (EPS) of ₹13.78 in 2025. The analysts are less bullish than they were before these results, given the reduced revenue forecasts and the minor downgrade to earnings per share expectations.

Despite the cuts to forecast earnings, there was no real change to the ₹407 price target, showing that the analysts don't think the changes have a meaningful impact on its intrinsic value. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Blue Jet Healthcare at ₹445 per share, while the most bearish prices it at ₹360. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Blue Jet Healthcare is an easy business to forecast or the the analysts are all using similar assumptions.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The analysts are definitely expecting Blue Jet Healthcare's growth to accelerate, with the forecast 35% annualised growth to the end of 2025 ranking favourably alongside historical growth of 11% per annum over the past three years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 10% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Blue Jet Healthcare is expected to grow much faster than its industry.

The Bottom Line

The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. They also downgraded Blue Jet Healthcare's revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. The consensus price target held steady at ₹407, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Blue Jet Healthcare going out to 2027, and you can see them free on our platform here..

Plus, you should also learn about the 1 warning sign we've spotted with Blue Jet Healthcare .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.